(R)-5-methyl-5-(p-tolyl)imidazolidine-2,4-dione | 169032-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (R)-5-methyl-5-(p-tolyl)imidazolidine-2,4-dione
• 英文别名: (5R)-5-methyl-5-(4-methylphenyl)imidazolidine-2,4-dione
• CAS: 169032-05-7
• 化学式: C₁₁H₁₂N₂O₂
• mdl: MFCD00068873
• 分子量: 204.228
• InChiKey: RTMDEHNRMKFSML-LLVKDONJSA-N

物化性质

• 密度：
  1.182±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-5-methyl-5-(p-tolyl)imidazolidine-2,4-dione 在 甲醇 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 78.25h， 生成 (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-(4-methylphenyl)propanoic acid
  参考文献：
  名称：

  新手性选择剂的设计和可扩展综合。第1部分：由非天然大体积氨基酸合成的新受限环肽的合成与表征

  摘要：

  我们描述了为手性识别设计的新型环肽的概念，合成和表征。不对称单元由一系列α-芳基-α-甲基甘氨酸中的非天然氨基酸构成。描述了对肽合成的标准方法的修改，以便在应用于受阻氨基酸时提高产量和纯度。公开了关于获得的环肽的宿主-客体能力的第一组实验。

  DOI：

  10.1016/j.tet.2011.06.032
• 作为产物：
  描述：

  5-甲基-5-（4-甲基苯基）咪唑烷-2,4-二酮 生成 (R)-5-methyl-5-(p-tolyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  An efficient access to the enantiomers of α-methyl-4-carboxyphenylglycine via a hydantoin route using a practical variant of preferential crysallization AS3PC (Auto Seeded Programmed Polythermic Preferential Crystallization)11

  摘要：

  The enantiomers are obtained in preparative amounts without a resolving agent via the following sequence: hydantoin synthesis, resolution by entrainment, and ring cleavage by means of hydrolysis in basic conditions. The new variant of preferential crystallization (AS3PC), implemented without using seeds, shows good reproducibility and yield. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00349-2

文献信息

• NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3321256A1

  公开（公告）日：2018-05-16

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗自身免疫性疾病（如类风湿性关节炎等）、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• Imide derivatives and use thereof as medicine
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10407408B2

  公开（公告）日：2019-09-10

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗类风湿性关节炎等自身免疫性疾病、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• EP3321256
  申请人：——

  公开号：——

  公开（公告）日：——
• Design and scalable synthesis of new chiral selectors. Part 1: Synthesis and characterization of a new constrained cyclopeptide from unnatural bulky amino acids
  作者：Laurent Ferron、Frédéric Guillen、Servane Coste、Gérard Coquerel、Pascal Cardinaël、Joël Schwartz、Jean-Marc Paris、Jean-Christophe Plaquevent

  DOI：10.1016/j.tet.2011.06.032

  日期：2011.8

  We describe the conception, synthesis, and characterization of a novel cyclopeptide designed for chiral recognition. The asymmetric units are built from an unnatural amino acid in the series of α-aryl-α-methyl glycine. Modifications of standard methods of peptide synthesis are described in order to improve yields and purities when applied to hindered amino acids. First set of experiments about host–guest

  我们描述了为手性识别设计的新型环肽的概念，合成和表征。不对称单元由一系列α-芳基-α-甲基甘氨酸中的非天然氨基酸构成。描述了对肽合成的标准方法的修改，以便在应用于受阻氨基酸时提高产量和纯度。公开了关于获得的环肽的宿主-客体能力的第一组实验。
• An efficient access to the enantiomers of α-methyl-4-carboxyphenylglycine via a hydantoin route using a practical variant of preferential crysallization AS3PC (Auto Seeded Programmed Polythermic Preferential Crystallization)11
  作者：E. Ndzié、P. Cardinael、A.-R. Schoofs、G. Coquerel

  DOI：10.1016/s0957-4166(97)00349-2

  日期：1997.9

  The enantiomers are obtained in preparative amounts without a resolving agent via the following sequence: hydantoin synthesis, resolution by entrainment, and ring cleavage by means of hydrolysis in basic conditions. The new variant of preferential crystallization (AS3PC), implemented without using seeds, shows good reproducibility and yield. (C) 1997 Elsevier Science Ltd.